Rly 4008
WebDec 1, 2024 · RLY-4008 is a highly selective and potent oral inhibitor designed to target both FGFR2 driver and resistance mutations. We initiated a first-in-human study in advanced … WebMay 28, 2024 · We initiated a first-in-human (FIH) precision oncology study of RLY-4008 in advanced solid tumor pts with FGFR2 alterations with primary objectives to define the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) and adverse event (AE) profile of RLY-4008 and key secondary objectives to assess FGFR2 genotype in blood and …
Rly 4008
Did you know?
WebOct 8, 2024 · About RLY-4008 RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. … WebAug 18, 2024 · About RLY-4008. RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties.
WebSep 26, 2024 · Alternative Names: RLY-4008. Latest Information Update: 26 Sep 2024. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual …
Web• RLY-4008 is a novel potent and highly selective FGFR2 inhibitor designed to overcome the emergence of on-target FGFR2 resistance mutations and dose-limiting toxicities associated with current pan-FGFR inhibitors. • RLY-4008 is > 200-fold selective over FGFR1, and > 80- and > 5000-fold selective over FGFR3 and FGFR4, respectively. Web• RLY-4008 is a novel potent and highly selective FGFR2 inhibitor designed to overcome the emergence of on-target FGFR2 resistance mutations and dose-limiting toxicities …
WebMar 10, 2024 · AACR is being held April 10-15 and May 17-21. The Company anticipates disclosing initial clinical data for RLY-4008 in the second half of 2024. Poster …
WebNov 1, 2024 · RLY-4008 is selective for FGFR2, and the majority of FGFR alterations in cholangiocarcinoma are FGFR2 fusions, Goyal says. Safety and tolerability are a concern when targeting FGFR , Goyal explains. citizens bank chat onlineWebReFocus (RLY-4008-101), a Phase 1/2 study (NCT04526106), enrolled pts with advanced solid tumors who received RLY-4008 orally (20-200 mg QD or BID). FGFR2 f/r status was … citizens bank charlotte ncWebThe company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective ... dickens coffee \u0026 tea roomWebOct 8, 2024 · In addition, RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models. RLY-4008 is currently being evaluated in a first-in-human clinical trial designed to evaluate the safety and tolerability of RLY-4008 in patients with advanced or metastatic FGFR2-altered solid … citizens bank chat nowWebSep 13, 2024 · About RLY-4008 RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. citizens bank chatsworth ilWebJan 4, 2024 · About RLY-4008 RLY-4008 is a potent and selective oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in many cancers, … citizens bank chat specialistWebFull Title A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Purpose … citizens bank chatsworth